Skip to content
Screener

Zevra Therapeutics, Inc. ZVRA Amortization of capitalized software and acquired intangible assets

Amortization of capitalized software and acquired intangible assets at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$73.49M+1,417%
XER
Xeris Biopharma Holdings, Inc.XERS
$2.71M0.0%
RFL
Rafael Holdings, Inc.RFL

Other financials

Income statement

See full
Revenue$39.7M+53.3%
Gross profit$38.1M+182%
Operating income$16.8M+124%
Net income$8.8M-88.3%
EPS (diluted)$0.14-88.4%

Balance sheet

See full
Cash & equivalents$145.3M+205%
Total debt$1.5M-97.6%
Total equity$217.7M+85.7%
Total assets$302.7M+18.1%

Cash flow

See full
Operating cash flow$17.0M+573%
CapEx$217.0K+1.9%
Free cash flow$16.8M+541%

Valuation

See full
Market cap$681.73M+6.6%
Enterprise value$537.9M-17.8%
P/E11.7×-230×
P/S-5.3×

Profitability

See full
Gross margin95.5%+23.5pp
Operating margin-103.9%-43.0pp
Net margin42.8%+38.6pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity34.8%+31.3pp
Debt / equity-0.5×
Current ratio5.2×-2.7×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.

The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001434647-26-000068
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Revenue, net$39,663$25,881$75,883$46,282
Cost of product revenue (excluding $316 and $1,616 in intangible asset amortization for the three months ended June 30, 2026, and 2025, respectively, and $632 and $3,231 in intangible asset amortization for the six months ended June 30, 2026, and 2025, respectively, shown separately below)(1,525)(12,379)(3,422)(13,724)
Intangible asset amortization(316)(1,616)(632)(3,231)
Impairment of intangible assets(58,710)(58,710)
Gain on sale of future royalties, intellectual property, and other assets, net43,314
Operating expenses:
Research and development(4,486)(3,433)(8,878)(6,691)
Selling, general and administrative(16,559)(20,782)(37,342)(40,327)

ITEM 1.FINANCIAL STATEMENTS

FAQ

What is Zevra Therapeutics, Inc.'s amortization of capitalized software and acquired intangible assets?
Zevra Therapeutics, Inc. (ZVRA) reported amortization of capitalized software and acquired intangible assets of $316K in Q2 2026.
How has Zevra Therapeutics, Inc.'s amortization of capitalized software and acquired intangible assets changed year-over-year?
Zevra Therapeutics, Inc.'s amortization of capitalized software and acquired intangible assets decreased by 80.4% year-over-year, from $1.62M to $316K.
What does amortization of capitalized software and acquired intangible assets mean?
Amortization of capitalized software and acquired intangible assets

Ask your AI about Zevra Therapeutics, Inc.'s amortization of capitalized software and acquired intangible assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude